Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001847493 | SCV002104904 | uncertain significance | Hereditary spastic paraplegia | 2017-07-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002034739 | SCV002312871 | uncertain significance | not provided | 2021-08-24 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with POLG2-related conditions. This sequence change replaces valine with isoleucine at codon 174 of the POLG2 protein (p.Val174Ile). The valine residue is weakly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is not present in population databases (ExAC no frequency). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |